Monoamine oxidase: radiotracer development and human studies.

[1]  K. Tipton,et al.  Monoamine oxidase inhibitors and the cheese effect , 1993, Neurochemical Research.

[2]  H. Kimura,et al.  Expression of monoamine oxidase B activity in astrocytes of senile plaques , 2004, Acta Neuropathologica.

[3]  R. Dolan,et al.  Measurement of human cerebral monoamine oxidase type B (MAO-B) activity with positron emission tomography (PET): a dose ranging study with the reversible inhibitor Ro 19-6327 , 2004, European Journal of Clinical Pharmacology.

[4]  P. Jatlow,et al.  A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation , 2003, Biological Psychiatry.

[5]  N. Volkow,et al.  PET imaging of monoamine oxidase B in peripheral organs in humans. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[6]  J. Fowler,et al.  Non‐MAO A binding of clorgyline in white matter in human brain , 2001, Journal of neurochemistry.

[7]  N. Volkow,et al.  Evidence that L-deprenyl treatment for one week does not inhibit MAO A or the dopamine transporter in the human brain. , 2001, Life sciences.

[8]  C. D. Arnett,et al.  Species differences in [11C]clorgyline binding in brain. , 2001, Nuclear medicine and biology.

[9]  R. Porsolt,et al.  Evaluation of a Ginkgo biloba Extract (EGb 761) in Functional Tests for Monoamine Oxidase Inhibition , 2000, Arzneimittelforschung.

[10]  N. Volkow,et al.  Maintenance of brain monoamine oxidase B inhibition in smokers after overnight cigarette abstinence. , 2000, The American journal of psychiatry.

[11]  R. Wurtman,et al.  Characterization of phentermine and related compounds as monoamine oxidase (MAO) inhibitors. , 2000, Biochemical pharmacology.

[12]  N. Volkow,et al.  Evidence that gingko biloba extract does not inhibit MAO A and B in living human brain. , 2000, Life sciences.

[13]  J S Fowler,et al.  Reproducibility of repeated measures of deuterium substituted [11C]L-deprenyl ([11C]L-deprenyl-D2) binding in the human brain. , 2000, Nuclear medicine and biology.

[14]  A. Khalil,et al.  Isolation and characterization of a monoamine oxidase inhibitor from tobacco leaves. , 2000, Chemical research in toxicology.

[15]  G. Cohen,et al.  Monoamine Oxidase and Mitochondrial Respiration , 1999, Journal of neurochemistry.

[16]  N. Volkow,et al.  Smoking a single cigarette does not produce a measurable reduction in brain MAO B in non-smokers. , 1999, Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco.

[17]  C. J. Van der Schyf,et al.  Species-dependent differences in monoamine oxidase A and B-catalyzed oxidation of various C4 substituted 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridinyl derivatives. , 1999, The Journal of pharmacology and experimental therapeutics.

[18]  J. Mukherjee,et al.  Development of N-[3-(2',4'-dichlorophenoxy)-2-18F-fluoropropyl]-N-methylpropargylamine (18F-fluoroclorgyline) as a potential PET radiotracer for monoamine oxidase-A. , 1999, Nuclear medicine and biology.

[19]  G. Bartzokis,et al.  Selegiline Effects on Cocaine-Induced Changes in Medial Temporal Lobe Metabolism and Subjective Ratings of Euphoria , 1999, Neuropsychopharmacology.

[20]  O. Scremin,et al.  Cerebral cortical blood flow maps are reorganized in MAOB-deficient mice , 1999, Brain Research.

[21]  G. Simpson,et al.  Schizophrenia, Monoamine Oxidase Activity, and Cigarette Smoking , 1999, Neuropsychopharmacology.

[22]  N. Volkow,et al.  Comparison of Brain Glucose Metabolism and Monoamine Oxidase B (MAO B) in Traumatic Brain Injury. , 1999, Clinical positron imaging : official journal of the Institute for Clinical P.E.T.

[23]  J. Corbett,et al.  Sensitivity of [11C]phenylephrine kinetics to monoamine oxidase activity in normal human heart. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[24]  C. C. Johnson,et al.  Smoking and Parkinson’s disease , 1999, Neurology.

[25]  P. Curtis‐Prior,et al.  Therapeutic Value of Ginkgo biloba in Reducing Symptoms of Decline in Mental Function , 1998, The Journal of pharmacy and pharmacology.

[26]  J. Shih,et al.  Monoamine oxidase: from genes to behavior. , 1999, Annual review of neuroscience.

[27]  N. Volkow,et al.  An acute dose of nicotine does not inhibit MAO B in baboon brain in vivo. , 1998, Life sciences.

[28]  B. Weber,et al.  Monoamine oxidase B single-photon emission tomography with [123I]Ro 43-0463: imaging in volunteers and patients with temporal lobe epilepsy , 1998, European Journal of Nuclear Medicine.

[29]  P. Malherbe,et al.  Monoamine oxidases: from brain maps to physiology and transgenics to pathophysiology. , 1998, Journal of neural transmission. Supplementum.

[30]  A. Buck,et al.  In vivo properties of N-(2-aminoethyl)-5-halogeno-2-pyridinecarboxamide 18F- and 123I-labelled reversible inhibitors of monoamine oxidase B. , 1998, Nuclear medicine and biology.

[31]  K. Tipton,et al.  Monoamine oxidases and related amine oxidases as phase I enzymes in the metabolism of xenobiotics. , 1998, Journal of neural transmission. Supplementum.

[32]  Takeshi Kumazawa,et al.  Increased stress response and β–phenylethylamine in MAOB–deficient mice , 1997, Nature Genetics.

[33]  J. Bloomquist,et al.  Potential metabolic bioactivation pathways involving cyclic tertiary amines and azaarenes. , 1997, Chemical research in toxicology.

[34]  M. Bergström,et al.  Synthesis of some 11C-labelled MAO-A inhibitors and their in vivo uptake kinetics in rhesus monkey brain. , 1997, Nuclear medicine and biology.

[35]  N. Volkow,et al.  Age-Related Increases in Brain Monoamine Oxidase B in Living Healthy Human Subjects , 1997, Neurobiology of Aging.

[36]  M. Bergström,et al.  11C-harmine as a tracer for monoamine oxidase A (MAO-A): in vitro and in vivo studies. , 1997, Nuclear medicine and biology.

[37]  P Woodbury,et al.  A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. , 1997, The New England journal of medicine.

[38]  M. Bergström,et al.  MAO-A inhibition in brain after dosing with esuprone, moclobemide and placebo in healthy volunteers: in vivo studies with positron emission tomography , 1997, European Journal of Clinical Pharmacology.

[39]  N. Volkow,et al.  Brain monoamine oxidase A inhibition in cigarette smokers. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[40]  J. Finberg,et al.  Effect of Long‐Term Treatment with Selective Monoamine Oxidase A and B Inhibitors on Dopamine Release from Rat Striatum In Vivo , 1996, Journal of neurochemistry.

[41]  M. Vila,et al.  Localization of monoamine oxidases in human peripheral tissues. , 1996, Life sciences.

[42]  N. Volkow,et al.  Deprenyl and levodopa and Parkinson's disease progression , 1996, Annals of neurology.

[43]  P. Jenner.  Hidden persuasion , 1996, Human & experimental toxicology.

[44]  R Kieburtz,et al.  Effect of lazabemide on the progression of disability in early Parkinson's disease , 1996, Annals of neurology.

[45]  B. Cohen,et al.  Treatment of Negative Symptoms in Schizophrenia and Schizoaffective Disorder by Selegiline Augmentation of Antipsychotic Medication: A Pilot Study Examining the Role of Dopamine , 1996, The Journal of nervous and mental disease.

[46]  O. Curet,et al.  THE DRAMBALLET STUDIO , 1996 .

[47]  K. Leenders,et al.  Radiosynthesis of [11C]brofaromine, a potential tracer for imaging monoamine oxidase A. , 1996, Nuclear medicine and biology.

[48]  B. Cooper,et al.  Extracts of Ginkgo biloba leaves inhibit monoamine oxidase. , 1996, Life sciences.

[49]  D. Guilloteau,et al.  An iodinated derivative of moclobemide as potential radioligand for brain MAO-A exploration. , 1996, Life sciences.

[50]  N. Volkow,et al.  Inhibition of monoamine oxidase B in the brains of smokers , 1996, Nature.

[51]  A. Puech,et al.  Monoamine oxidase A and B activities in heavy smokers , 1995, Biological Psychiatry.

[52]  P. Schubiger,et al.  [123I18F] N-(2-aminoethyl)-5-halogeno-2-pyridinecarbox-amides, site specific tracers for MAO-B mapping with SPET and PET☆ , 1995 .

[53]  A. Wolf,et al.  Plasma input function determination for PET using a commercial laboratory robot. , 1995, Nuclear medicine and biology.

[54]  Y. Lecrubier,et al.  A reversible monoamine oxidase A inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers , 1995, Clinical pharmacology and therapeutics.

[55]  P. Schubiger,et al.  123I-labeling and evaluation of Ro 43-0463, a SPET tracer for MAO-B imaging. , 1995, Nuclear medicine and biology.

[56]  B. Långstrom,et al.  Mao-a enzyme binding in bladder-cancer characterized with [C-11] harmine in frozen-section autoradiography. , 1995, Oncology reports.

[57]  N. Volkow,et al.  Mechanistic Positron Emission Tomography Studies of 6‐[18F]Fluorodopamine in Living Baboon Heart: Selective Imaging and Control of Radiotracer Metabolism Using the Deuterium Isotope Effect , 1995, Journal of neurochemistry.

[58]  D. Guilloteau,et al.  Iododerivative of pargyline: a potential tracer for the exploration of monoamine oxidase sites by SPECT. , 1995, Nuclear medicine and biology.

[59]  Gunnar Antoni,et al.  Positron Emission Tomography with [11C]Deuterium‐Deprenyl in Temporal Lobe Epilepsy , 1995, Epilepsia.

[60]  N. Volkow,et al.  Selective reduction of radiotracer trapping by deuterium substitution: comparison of carbon-11-L-deprenyl and carbon-11-deprenyl-D2 for MAO B mapping. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[61]  P. Gaspar,et al.  Aggressive behavior and altered amounts of brain serotonin and norepinephrine in mice lacking MAOA. , 1995, Science.

[62]  D. Morens,et al.  Cigarette smoking and protection from Parkinson's disease , 1995, Neurology.

[63]  R. Ramsay,et al.  Monoamine oxidases: old friends hold many surprises , 1995, The FASEB Journal.

[64]  Y. Magata,et al.  Evaluation of radioiodinated iodoclorgyline as a SPECT radiopharmaceutical for MAO-A in the brain. , 1995, Nuclear medicine and biology.

[65]  N. Volkow,et al.  Slow recovery of human brain MAO B after L‐Deprenyl (Selegeline) withdrawal , 1994, Synapse.

[66]  V. Chan‐Palay,et al.  Increased monoamine oxidase b activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography , 1994, Neuroscience.

[67]  J. Saura,et al.  Differential age-related changes of mao-a and mao-b in mouse brain and pe peripheral organs , 1994, Neurobiology of Aging.

[68]  M. Nelen,et al.  Abnormal behavior associated with a point mutation in the structural gene for monoamine oxidase A. , 1993, Science.

[69]  N. Volkow,et al.  Monoamine oxidase B (MAO B) inhibitor therapy in Parkinson's disease , 1993, Neurology.

[70]  P. Yu,et al.  Rescue of axotomized immature rat facial motoneurons by R(-)-deprenyl: stereospecificity and independence from monoamine oxidase inhibition , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[71]  G. Belle,et al.  Relationship between cigarette smoking and Alzheimer's disease in a population‐based case‐control study , 1992, Neurology.

[72]  I. Kopin.  Monoamine oxidase (MAO): relationships to foods, poisons and medicines , 1993 .

[73]  B. Spännare,et al.  In Vitro Quantitative Autoradiography of [3H]‐L‐Deprenyl and [3H]‐PK 11195 Binding Sites in Human Epileptic Hippocampus , 1992, Epilepsia.

[74]  P. Riederer,et al.  The molecular pharmacology of L-deprenyl. , 1992, European journal of pharmacology.

[75]  J. Saura,et al.  Quantitative enzyme radioautography with 3H-Ro 41-1049 and 3H-Ro 19- 6327 in vitro: localization and abundance of MAO-A and MAO-B in rat CNS, peripheral organs, and human brain , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[76]  L. Schneider,et al.  Clinical and biochemical aspects of depressive disorders: III. Treatment and controversies , 1992, Synapse.

[77]  D. Murphy,et al.  Clinical, biochemical, and neuropsychiatric evaluation of a patient with a contiguous gene syndrome due to a microdeletion Xp11.3 including the Norrie disease locus and monoamine oxidase (MAOA and MAOB) genes. , 1992, American journal of medical genetics.

[78]  Jean Logan,et al.  Effects of endogenous dopamine on measures of [18F]N‐methylspiroperidol binding in the basal ganglia: Comparison of simulations and experimental results from PET studies in baboons , 1991, Synapse.

[79]  L. Oreland.  Monoamine oxidase, dopamine and Parkinson's disease , 1991, Acta neurologica Scandinavica. Supplementum.

[80]  R. Frackowiak,et al.  Measurement of Cerebral Monoamine Oxidase B Activity Using L-[11C]Deprenyl and Dynamic Positron Emission Tomography , 1991, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[81]  W. Koller,et al.  Selegiline HCl: Selective MAO‐type B inhibitor , 1990, Neurology.

[82]  J. Helzer,et al.  Smoking, smoking cessation, and major depression. , 1990, JAMA.

[83]  A. Wolf,et al.  Synthesis of (R)-(-)- and (S)-(+)-4-fluorodeprenyl and (R)-(-)- and (S)-(+)-[N-11C-methyl]-4-fluorodeprenyl and positron emission tomography studies in baboon brain. , 1990, Journal of medicinal chemistry.

[84]  J. Henningfield,et al.  Involvement of tobacco in alcoholism and illicit drug use. , 1990, British journal of addiction.

[85]  W. Koller,et al.  Selegiline HCl : selective MAO-type B inhibitor. Discussion , 1990 .

[86]  M. Serio,et al.  Catecholamines and blood pressure regulation. , 1990, Hormone Research.

[87]  J. Langston,et al.  The effect of deprenyl (selegiline) on the natural history of Parkinson's disease. , 1989, Science.

[88]  M. Strolin Benedetti,et al.  Monoamine oxidase, brain ageing and degenerative diseases. , 1989, Biochemical pharmacology.

[89]  Anthony E. Lang,et al.  Effect of deprenyl on the progression of disability in early Parkinson's disease. , 1989, The New England journal of medicine.

[90]  B. Långström,et al.  11C-labelling of dimethylphenethylamine in two different positions and biodistribution studies. , 1989, International journal of radiation applications and instrumentation. Part A, Applied radiation and isotopes.

[91]  T. Halonen,et al.  Dopaminergic system and monoamine oxidase-B Activity in Alzheimer's disease , 1988, Neurobiology of Aging.

[92]  A. Wolf,et al.  Mechanistic Positron Emission Tomography Studies: Demonstration of a Deuterium Isotope Effect in the Monoamine Oxidase‐Catalyzed Binding of [11C]l‐Deprenyl in Living Baboon Brain , 1988, Journal of neurochemistry.

[93]  M. Hogan,et al.  The in vitro insertion of monoamine oxidase B into mitochondrial outer membranes , 1988, FEBS letters.

[94]  P. Seeburg,et al.  cDNA cloning of human liver monoamine oxidase A and B: molecular basis of differences in enzymatic properties. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[95]  R. M. Rose,et al.  Localization of distinct monoamine oxidase a and monoamine oxidase b cell populations in human brainstem , 1988, Neuroscience.

[96]  A. Wolf,et al.  Synthesis of suicide inhibitors of monoamine oxidase: Carbon‐11 labeled clorgyline, L‐deprenyl and D‐deprenyl , 1988 .

[97]  Inoue Osamu,et al.  [13N]-β-phenethylamine ([13N]PEA): A prototype tracer for measurement of MAO-B activity in heart , 1987 .

[98]  C. D. Arnett,et al.  Turnover of Brain Monoamine Oxidase Measured In Vivo by Positron Emission Tomography Using l‐[11C]Deprenyl , 1987, Journal of neurochemistry.

[99]  R. DeTeresa,et al.  Neocortical cell counts in normal human adult aging , 1987, Annals of neurology.

[100]  M. Iyo,et al.  Kinetics of [11C]N,N-dimethylphenylethylamine in mice and humans: potential for measurement of brain MAO-B activity. , 1987, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[101]  Trevor R. Norman,et al.  Platelet monoamine oxidase: Low activity in cigarette smokers , 1987, Psychiatry Research.

[102]  C. D. Arnett,et al.  Mapping human brain monoamine oxidase A and B with 11C-labeled suicide inactivators and PET. , 1987, Science.

[103]  P. Riederer,et al.  Monoamine Oxidase Activity and Monoamine Metabolism in Brains of Parkinsonian Patients Treated with l‐Deprenyl , 1986, Journal of neurochemistry.

[104]  O. Inoue,et al.  Deuterium isotope effect of [11C1]N,N-dimethylphenethyl-amine-alpha,alpha-d2; reduction in metabolic trapping rate in brain. , 1986, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.

[105]  J R Hughes,et al.  Prevalence of smoking among psychiatric outpatients. , 1986, The American journal of psychiatry.

[106]  D. Keller.  MAO inhibitors , 1986, Cleveland Clinic journal of medicine.

[107]  Robinson Jb.  Stereoselectivity and isoenzyme selectivity of monoamine oxidase inhibitors: Enantiomers of amphetamine, n-methylamphetamine and deprenyl , 1985 .

[108]  Lars Lidberg,et al.  Platelet monoamine oxidase activity and psychopathy , 1985, Psychiatry Research.

[109]  J S Fowler,et al.  Selective, irreversible in vivo binding of [11C]clorgyline and [11C]-L-deprenyl in mice: potential for measurement of functional monoamine oxidase activity in brain using positron emission tomography. , 1985, Biochemical pharmacology.

[110]  K. Ishiwata,et al.  Biodistribution of a positron-emitting suicide inactivator of monoamine oxidase, carbon-11 pargyline, in mice and a rabbit. , 1985, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[111]  O. Inoue,et al.  Radioactive N,N‐Dimethylphenylethylamine: A Selective Radiotracer for In Vivo Measurement of Monoamine Oxidase‐B Activity in the Brain , 1985, Journal of neurochemistry.

[112]  R. Duvoisin,et al.  Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors , 1984, Nature.

[113]  J. Langston,et al.  Pargyline prevents MPTP-induced parkinsonism in primates. , 1984, Science.

[114]  P. Riederer,et al.  Deprenyl prolongs the therapeutic efficacy of combined L-DOPA in Parkinson's disease. , 1984, Advances in neurology.

[115]  C S Patlak,et al.  Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data , 1983, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[116]  J. Langston,et al.  Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. , 1983, Science.

[117]  R. Abeles.  Suicide enzyme inactivators. , 1976, Basic life sciences.

[118]  C. Walsh.  Suicide substrates: mechanism-based enzyme inactivators , 1982 .

[119]  L. Oreland,et al.  Low platelet monoamine oxidase activity in cigarette smokers. , 1981, Life sciences.

[120]  B. Winblad,et al.  Increased activity of brain and platelet monoamine oxidase in dementia of Alzheimer type. , 1980, Life sciences.

[121]  A. Maycock,et al.  The structure of the covalent adduct formed by the interaction of 3-dimethylamino-1-propyne and the flavine of mitochondrial amine oxidase. , 1976, Biochemistry.

[122]  K. Magyar,et al.  Some puzzling pharmacological effects of monoamine oxidase inhibitors. , 1972, Advances in biochemical psychopharmacology.

[123]  J. Davis,et al.  Relation of sex and aging to monoamine oxidase activity of human brain, plasma, and platelets. , 1971, Archives of general psychiatry.

[124]  J. P. Johnston.  Some observations upon a new inhibitor of monoamine oxidase in brain tissue. , 1968, Biochemical pharmacology.

[125]  J. Schildkraut,et al.  The catecholamine hypothesis of affective disorders: a review of supporting evidence. , 1965, The American journal of psychiatry.

[126]  B. Belleau,et al.  DEUTERIUM ISOTOPE EFFECTS IN RELATION TO THE CHEMICAL MECHANISM OF MONOAMINE OXIDASE * , 1963, Annals of the New York Academy of Sciences.

[127]  G. Crane.  The psychiatric side-effects of iproniazid. , 1956, American Journal of Psychiatry.

[128]  E. Berman,et al.  Amine oxidases. XI. Inhibition of monoamine oxidase by 1-isonicotinyl-2-isopropylhydrazine. , 1955, The Journal of biological chemistry.

[129]  I. Selikoff,et al.  Treatment of pulmonary tuberculosis with hydrazide derivatives of isonicotinic acid. , 1952, Journal of the American Medical Association.

[130]  E. Zeller.  Über den enzymatischen Abbau von Histamin und Diaminen. 2. Mitteilung , 1938 .

[131]  H. Blaschko,et al.  The inactivation of adrenaline , 1937, The Journal of physiology.

[132]  M. Hare,et al.  Tyramine oxidase: A new enzyme system in liver. , 1928, The Biochemical journal.